Factors associated with increased stroke risk in AF patients include history of prior stroke/TIA, hypertension and diabetes, and advancing age. If not treated with anticoagulants, AF is associated with a 2.1-fold increase in risk for recurrent stroke and a 2.4-fold increase in risk for recurrent severe stroke. This presentation will review the use of the CHADS2 score to assess stroke risk in patients with AF; discuss the benefits versus risks of antithrombotic therapy for stroke risk reduction in AF patients, describe appropriate therapies for AF patients depending on the level of stroke risk, and review long-term management of AF patients receiving antithrombotic therapy.
This webcast was recorded live and is being used with the permission of the presenter.
- Use the CHADS2 score to assess stroke risk in patients with atrial fibrillation (AF)
- Recognize the benefits versus risks of antithrombotic therapy for stroke risk reduction in AF patients
- Identify appropriate therapeutic inventions for AF patients depending on the level of stroke risk
- Optimize the long-term management of AF patients receiving antithrombotic therapy
AMA PRA Category 1 Credit(s)TM
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The National Association for Continuing Education designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Elizabeth A. Jackson, MD, MPH
Associate Professor of Internal Medicine in the Division of Cardiovascular Medicine
University of Michigan
Ann Arbor, Michigan
Elizabeth A Jackson, MD, MPH, Speaker, is a consulant for McKesson, Inc., Up-to-Date, American College of Cardiology, National Institutes of Health, and a speaker for Annenberg Center for Health Sciences
Gregg Sherman, MD, Course Director, has no relationships to disclose.
Michelle Frisch, MPH, Activity Planning Committee, has no relationships to disclose.
Alan Goodstat, LCSW, Activity Planning Committee, has no relationships to disclose.
Harvey Parker, PhD, Activity Planning Committee, has no relationships to disclose.
Jan Basile, MD, Activity Planning Commitee, serves as a consultant to Forest and Takeda; and on the speakers' bureaus for Forest, Daiichi-Sankyo, and Takeda.
Valerian Fernandes, MD, Activity Planning Committee, has no relationships to disclose.
Louis Kuritzky, MD, Activity Planning Committee, serves as a speaker for Boehringer-Ingelheim.
None of the peer reviewers have any relevant financial relationships to disclose.
National Association for Continuing Education
Boehringer-Ingelheim Pharmaceuticals, Inc. provided commercial support for this enduring activity.
To obtain credit, a score of 60% or better is required. This CE is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test, and received your digital copy of your credit certificate. Your online certificate will be saved on myCME.com within your Profile/Exam History, which you can then access at any time.
WINDOWS PC SYSTEM REQUIREMENTS:
266-MHz Pentium II; Windows 98 or higher; 64 MB RAM; 800 x 600 screen resolution
set for “High Color (16-Bit)”; Macromedia Flash Player 6 or higher.
MACINTOSH® SYSTEM REQUIREMENTS:
Power Mac g3 at 300 MHz; System 8.5 or higher (excluding Mac OSX); 96 MB RAM; 20
MB minimum hard disk space available; 800 x 600 screen resolution set to “Thousands
of Colors”; Macromedia Flash Player 6 or higher.